Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

Business Wire 18-Jul-2017 9:00 AM

PBT434, Pranas lead drug in preclinical development for movement disorders, to be profiled in collaborative venture

MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)-- Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a research collaboration with Takeda Pharmaceuticals International, Inc. to study the ability of Pranas investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system.

One of the important non-motor features of Parkinsons disease is often the early presentation of severe and disabling impairment of gastrointestinal function. Parkinsons disease is characterised by the loss of neurons and their networks in the brain and in the gut. The cause of neurodegeneration and gastrointestinal dysfunction in Parkinsons disease is not known, but the protein alpha-synuclein has been hypothesized to be implicated in this process.

Prana recently announced the publication of results with PBT434 demonstrating significant reduction of alpha-synuclein in various pre-clinical models of Parkinsons disease in the paper entitled, The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsons disease in the peer reviewed journal Acta Neuropathologica Communications *. This paper suggested that PBT434 may reduce the formation of toxic alpha-synuclein fibrils and aggregates, rescue neurons burdened by such toxic forms of alpha-synuclein and restore motor function in animal models.

The research collaboration will investigate the ability of investigational compound PBT434 to mitigate gastrointestinal dysfunction; constipation, lowered colon motility and inflammation in mouse models, including an alpha-synuclein transgenic mouse.

Associate Professor David Finkelstein, Pranas Senior Scientific Consultant and Head of the Parkinsons Disease Laboratory at the Florey Institute of Neuroscience and Mental Health (Melbourne), said: This early research is important because our major therapeutic objective is to treat these disabling symptoms and provide an early therapeutic intervention for both motor and non-motor Parkinsonian symptoms in patients which may significantly impact on the quality of life.

PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was specifically designed to block the accumulation and aggregation of alpha-synuclein and is expected to begin human testing in a Phase 1 trial later this year.

*The peer reviewed article can be accessed from: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-017-0456-2

About Prana Biotechnology Limited Prana Biotechnology was established to commercialise research into neurodegenerative diseases such as Alzheimer's disease, Huntington disease, and Parkinsonian disease. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Pranas technology.

For further information please visit the Companys web site at www.pranabio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170718005490/en/

for Prana BiotechnologyInvestor RelationsWE BuchanRebecca Wilson, +61 3 9866 4722rwilson@buchanwe.com.auorMediaWE BuchanScott Newstead, +61 3 9866 4722snewstead@buchanwe.com.au

Source: Prana Biotechnology Ltd